Search company, investor...

SkinScience Labs

drdenese.com

Founded Year

2000

Stage

Acquired | Acquired

Revenue

$0000 

About SkinScience Labs

SkinScience Labs produces serums for the skin such as anti-aging skincare products and others aimed to revitalize and rejuvenate the skin.On April 30th, 2020, SkinScience Labs was acquired by CannaWorx. Terms of the transaction were not disclosed.

Headquarters Location

725 Grand Avenue Suite 201

Ridgefield, New Jersey, 07657,

United States

866-642-3754

Missing: SkinScience Labs's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: SkinScience Labs's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

SkinScience Labs Patents

SkinScience Labs has filed 1 patent.

The 3 most popular patent topics include:

  • Cosmetics
  • Cosmetics brands
  • Personal care brands
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/13/2017

11/5/2019

Skin care, Cosmetics, Cosmetics brands, Personal care brands, Shampoos

Grant

Application Date

6/13/2017

Grant Date

11/5/2019

Title

Related Topics

Skin care, Cosmetics, Cosmetics brands, Personal care brands, Shampoos

Status

Grant

Latest SkinScience Labs News

Pressure Biosciences Partners with Academic and Industry Leaders to Revolutionize Food, Wellness and Biomedical Spaces

Aug 27, 2021

{{following ? "Following" : "Follow"}} Advertiser Disclosure The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. The content that follows is for informational purposes only and not intended to be investing advice. August 27, 2021 9:38am  739  Comments Share: Image Provided By Pixabay Pressure Biosciences, Inc. (OTCQB: PBIO ), the pioneer behind innovative, broadly applicable pressure-based technology, has been aggressively pursuing strategic partnerships with academic and industry leaders, including Ohio State University and a range of multibillion-dollar pharmaceutical companies. Through these partnerships, Pressure Biosciences (PBI) hopes to roll out its pressure-based technology across the wide range of industries where it has the most potential to make an impact. Here are some of those existing and planned partnerships and what consumers and investors can expect to see from them. Ohio State University Partnership Forms Food Industry Consortium One of the most lucrative and promising partnerships PBI has entered into is its partnership with Ohio State University. Together, the two institutions formed the food industry consortium . Food and beverage companies who join the member-based consortium will receive first look right at PBI’s Ultra Shear Technology (UST) platform. The UST platform, which produces shelf-stable nanoemulsions of oil-based nutrients and ingredients, has broad applications across the food and beverage space. Two of the leading breakthroughs driven by the new tech are the nanoemulsions of CBD oil and the highly potent antioxidant, astaxanthin. These more potent nanoemulsions can be infused into food and beverages to offer health and wellness products to consumers worldwide. The dues paid by consortium members will go toward funding additional research, including the development of an industrial scale prototype of the UST platform that could be used to mass produce high quality nanoemulsions, making the tech viable for larger clients in the industry. PBI aims to sign at least two major food and beverage licensing agreements through this consortium before the end of 2021. Cannaworx Partnership Leads to Cannabis-Based Health and Skincare Line PBI’s pending merger partner, Cannaworx, has already successfully implemented the UST platform in the production of a growing line of hemp-based wellness and skincare products, including the December 2020 launch of ImmunaZin™ , a proprietary blend of 44 amino acid fragments in a hemp oil emulsion that helps stimulate T helper cells in the human body — the cells responsible for doing the work of your immune system. Together, the partners have worked to acquire additional product lines, like SkinScience Labs and Five Leaf Labs , in their effort to launch new health, wellness, and skincare products throughout 2021 and expand their distribution network. Major BaroFold Licensing Partnerships Work Toward Groundbreaking New Treatments Predating its innovative UST platform, PBI’s BaroFold technology offers similar pressure-based technology that has revolutionized the biomedical space. Through licensing partnerships for its BaroFold platform, PBI is helping advance the development of protein-based drugs. Protein-based drugs can be better targeted and cause fewer adverse effects than chemical-based drugs in many diseases — especially cancer, inflammatory diseases and autoimmune disorders. One of the key issues holding the industry back, though, is the challenges of developing these drugs, especially at scale. The process of folding and combining proteins is difficult and riddled with multiple points for potential error. BaroFold eliminates those challenges and provides a consistent, efficient process for developing stable, potent protein-based therapeutics. By licensing its platform to partners in the biopharmaceutical space, PBI can not only do its part to advance medicine by offering a scalable, efficient way to mass produce these more effective and safer protein-based drugs for patients around the world, but it can also collect recurring royalty fees as it does so, thus securing its piece of this estimated $228 billion market . PBI has already doubled its client base this year, signing new multibillion-dollar pharmaceutical clients and advancing one client to a higher production scale Stage 2 contract. It aims to advance at least one more client to a Stage 2 contract before the end of 2021. Leica Microsystems Partnership Could Revolutionize Diagnostics PBI announced a co-marketing agreement with Leica Microsystems this past March. The respected microscope manufacturer will work with PBI to develop an advanced diagnostics process that researchers and lab technicians can use to better detect cancer and disease progression in biopsies. By pairing Leica’s new laser microscopes with PBI’s Pressure Cycling Technology (PCT) platform, researchers can laser cut a precise section of a patient’s biopsy, break it down into its component proteins and nucleic acids with the PCT platform, and then send it to a mass spectrometer to look for biomarkers of disease. Currently in the planning stages, PBI aims to unveil the Leica-PBI collaborative workflow process by the end of 2021. © 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Related Articles (PBIO)

SkinScience Labs Frequently Asked Questions (FAQ)

  • When was SkinScience Labs founded?

    SkinScience Labs was founded in 2000.

  • Where is SkinScience Labs's headquarters?

    SkinScience Labs's headquarters is located at 725 Grand Avenue , Ridgefield.

  • What is SkinScience Labs's latest funding round?

    SkinScience Labs's latest funding round is Acquired.

  • Who are the investors of SkinScience Labs?

    Investors of SkinScience Labs include CannaWorx.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.